Radiopharmacokinetic modelling and radiation dose assessment of ²²³Ra used for treatment of metastatic castration-resistant prostate cancer.

ABSTRACT:

Purpose

Ra-223 dichloride (²²³Ra, Xofigo®) is used for treatment of patients suffering from castration-resistant metastatic prostate cancer. The objective of this work was to apply the most recent biokinetic model for radium and its progeny to show their radiopharmacokinetic behaviour. Organ absorbed doses after intravenous injection of ²²³Ra were estimated and compared to clinical data and data of an earlier modelling study.

Methods

The most recent systemic biokinetic model of ²²³Ra and its progeny, developed by the International Commission on Radiological Protection (ICRP), as well as the ICRP human alimentary tract model were applied for the radiopharmacokinetic modelling of Xofigo® biodistribution in patients after bolus administration. I

SUBMITTER: Hollriegl V 

PROVIDER: S-EPMC8172819 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature